Multiple myeloma is an incurable cancer characterized by the uncontrolled growth of
malignant plasma cells nurtured within a permissive bone marrow microenvironment. While …

Immuno‐oncology therapies engage the immune system to treat cancer. BiTE (bispecific T‐
cell engager) technology is a targeted immuno‐oncology platform that connects patients' …

Over the past 20 years, the regulatory approval of several novel agents to treat multiple
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …

Over the past decades, immunotherapy has demonstrated a prominent clinical efficacy in a
wide variety of human tumors. For many years, apoptosis has been considered a non …

The progression of multiple myeloma, a hematologic malignancy characterized by
unregulated plasma cell growth, is associated with increasing innate and adaptive immune …

Two mechanisms are involved in the immune escape of cancer cells: the immunoediting of
tumor cells and the suppression of the immune system. Both processes have been revealed …

Multiple myeloma (MM) and its precursor monoclonal gammopathy of undetermined
significance (MGUS) are distinct disorders that likely originate in the setting of chronic …

Multiple myeloma (MM) is a clonal plasma cell malignancy affecting a predominantly elderly
population. The continued development of newer therapies with novel mechanisms of action …

Panobinostat represents a potent oral nonselective pan‐histone deacetylase inhibitor
(HDAC) with activity in myeloma patients. It has been approved by the FDA and EMA in …

Multiple myeloma (MM) is an incurable malignancy of plasma cells that grow within a
permissive bone marrow microenvironment (BMM). The bone marrow milieu supports the …